Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer

Por Na, Il-Kang, le Coutre, Philipp
Publicado no Biomark Insights (2015)

Clinical Lessons to Be Learned from Patients Developing Chronic Myeloid Leukemia While on Immunosuppressive Therapy after Solid Organ Transplantation: Yet Another Case after Orthot...

Por Oberender, Christian, Kleeberg, Lorenz, Nienhues, Nicola, Gresse, Martin, Dörken, Bernd, Riess, Hanno, le Coutre, Philipp
Publicado no Case Rep Hematol (2014)

Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia

Por Kim, Theo D., Türkmen, Seval, Schwarz, Michaela, Koca, Gökben, Nogai, Hendrik, Bommer, Christiane, Dörken, Bernd, Daniel, Peter, le Coutre, Philipp
Publicado em 2010

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

Por Schiffer, Charles A., Cortes, Jorge E., Hochhaus, Andreas, Saglio, Giuseppe, le Coutre, Philipp, Porkka, Kimmo, Mustjoki, Satu, Mohamed, Hesham, Shah, Neil P.
Publicado no Cancer (2016)

Clinical cardiac safety profile of nilotinib

Por Kim, Theo D., le Coutre, Philipp, Schwarz, Michaela, Grille, Peggy, Levitin, Michal, Fateh-Moghadam, Suzanne, Giles, Francis J., Dörken, Bernd, Haverkamp, Wilhelm, Köhncke, Clemens
Publicado em 2012

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study

Por Hochhaus, Andreas, Baccarani, Michele, Giles, Francis J., le Coutre, Philipp D., Müller, Martin C., Reiter, Andreas, Santanastasio, Helene, Leung, Mimi, Novick, Steven, Kantarjian, Hagop M.
Publicado no J Cancer Res Clin Oncol (2015)

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

Por Cortes, Jorge E., Hochhaus, Andreas, le Coutre, Philipp D., Rosti, Gianantonio, Pinilla-Ibarz, Javier, Jabbour, Elias, Gillis, Kathryn, Woodman, Richard C., Blakesley, Rick E., Giles, Francis J., Kantarjian, Hagop M., Baccarani, Michele
Publicado em 2011

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

Por Shah, Neil P., Guilhot, François, Cortes, Jorge E., Schiffer, Charles A., le Coutre, Philipp, Brümmendorf, Tim H., Kantarjian, Hagop M., Hochhaus, Andreas, Rousselot, Philippe, Mohamed, Hesham, Healey, Diane, Cunningham, Michael, Saglio, Giuseppe
Publicado no Blood (2014)

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imati...

Por Hughes, Timothy P., Hochhaus, Andreas, Kantarjian, Hagop M., Cervantes, Francisco, Guilhot, François, Niederwieser, Dietger, le Coutre, Philipp D., Rosti, Gianantonio, Ossenkoppele, Gert, Lobo, Clarisse, Shibayama, Hirohiko, Fan, Xiaolin, Menssen, Hans D., Kemp, Charisse, Larson, Richard A., Saglio, Giuseppe
Publicado em 2014

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP...

Por Al-Ali, Haifa Kathrin, Griesshammer, Martin, le Coutre, Philipp, Waller, Cornelius F., Liberati, Anna Marina, Schafhausen, Philippe, Tavares, Renato, Giraldo, Pilar, Foltz, Lynda, Raanani, Pia, Gupta, Vikas, Tannir, Bayane, Ronco, Julian Perez, Ghosh, Jagannath, Martino, Bruno, Vannucchi, Alessandro M.
Publicado no Haematologica (2016)

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance

Por Jabbour, Elias, le Coutre, Philipp D., Cortes, Jorge, Giles, Francis, Bhalla, Kapil N., Pinilla-Ibarz, Javier, Larson, Richard A., Gattermann, Norbert, Ottmann, Oliver G., Hochhaus, Andreas, Hughes, Timothy P., Saglio, Giuseppe, Radich, Jerald P., Kim, Dong-Wook, Martinelli, Giovanni, Reynolds, John, Woodman, Richard C., Baccarani, Michele, Kantarjian, Hagop M.
Publicado em 2012

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

Por Kantarjian, Hagop M., Giles, Francis J., Bhalla, Kapil N., Pinilla-Ibarz, Javier, Larson, Richard A., Gattermann, Norbert, Ottmann, Oliver G., Hochhaus, Andreas, Radich, Jerald P., Saglio, Giuseppe, Hughes, Timothy P., Martinelli, Giovanni, Kim, Dong-Wook, Shou, Yaping, Gallagher, Neil J., Blakesley, Rick, Baccarani, Michele, Cortes, Jorge, le Coutre, Philipp D.
Publicado no Blood (2011)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome

Por Botezatu, Lacramioara, Michel, Lars C., Makishima, Hideki, Schroeder, Thomas, Germing, Ulrich, Haas, Rainer, van der Reijden, Bert, Marneth, Anne E., Bergevoet, Saskia M., Jansen, Joop H., Przychodzen, Bartlomiej, Wlodarski, Marcin, Niemeyer, Charlotte, Platzbecker, Uwe, Ehninger, Gerhard, Unnikrishnan, Ashwin, Beck, Dominik, Pimanda, John, Hellström-Lindberg, Eva, Malcovati, Luca, Boultwood, Jacqueline, Pellagatti, Andrea, Papaemmanuil, Elli, Le Coutre, Philipp, Kaeda, Jaspal, Opalka, Bertram, Möröy, Tarik, Dührsen, Ulrich, Maciejewski, Jaroslaw, Khandanpour, Cyrus
Publicado no Exp Hematol (2016)

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

Por Abboud, Camille, Berman, Ellin, Cohen, Adam, Cortes, Jorge, DeAngelo, Daniel, Deininger, Michael, Devine, Steven, Druker, Brian, Fathi, Amir, Jabbour, Elias, Jagasia, Madan, Kantarjian, Hagop, Khoury, Jean, Laneuville, Pierre, Larson, Richard, Lipton, Jeffrey, Moore, Joseph O., Mughal, Tariq, O’Brien, Susan, Pinilla-Ibarz, Javier, Quintas-Cardama, Alfonso, Radich, Jerald, Reddy, Vishnu, Schiffer, Charles, Shah, Neil, Shami, Paul, Silver, Richard T., Snyder, David, Stone, Richard, Talpaz, Moshe, Tefferi, Ayalew, Van Etten, Richard A., Wetzler, Meir, Abruzzese, Elisabetta, Apperley, Jane, Breccia, Massimo, Byrne, Jenny, Cervantes, Francisco, Chelysheva, Ekaterina, Clark, R. E., de Lavallade, Hugues, Dyagil, Iryna, Gambacorti-Passerini, Carlo, Goldman, John, Haznedaroglu, Ibrahim, Hjorth-Hansen, Henrik, Holyoake, Tessa, Huntly, Brian, le Coutre, Philipp, Lomaia, Elza, Mahon, Francois-Xavier, Marin-Costa, David, Martinelli, Giovanni, Mayer, Jiri, Milojkovic, Dragana, Olavarria, Eduardo, Porkka, Kimmo, Richter, Johan, Rousselot, Philippe, Saglio, Giuseppe, Saydam, Guray, Stentoft, Jesper, Turkina, Anna, Vigneri, Paolo, Zaritskey, Andrey, Aguayo, Alvaro, Ayala, Manuel, Bendit, Israel, Maria Bengio, Raquel, Best, Carlos, Bullorsky, Eduardo, Cervera, Eduardo, DeSouza, Carmino, Fanilla, Ernesto, Gomez-Almaguer, David, Hamerschlak, Nelson, Lopez, Jose, Magarinos, Alicia, Meillon, Luis, Milone, Jorge, Moiraghi, Beatriz, Pasquini, Ricardo, Pavlovsky, Carolina, Ruiz-Arguelles, Guillermo J., Spector, Nelson, Arthur, Christopher, Browett, Peter, Grigg, Andrew, Hu, Jianda, Huang, Xiao-jun, Hughes, Tim, Jiang, Qian, Jootar, Saengsuree, Kim, Dong-Wook, Malhotra, Hemant, Malhotra, Pankaj, Matsumura, Itaru, Melo, Junia, Ohnishi, Kazunori, Ohno, Ryuzo, Saikia, Tapan, Schwarer, Anthony P., Takahashi, Naoto, Tam, Constantine, Tauchi, Tetsuzo, Usuki, Kensuke, Wang, Jianxiang, Abdel-Rahman, Fawzi, Deeb Saeed Aljurf, Mahmoud, Bazarbachi, Ali, Ben Yehuda, Dina, Chaudhri, Naeem, Durosinmi, Muheez, Kamel, Hossam, Louw, Vernon, Francis Matti, Bassam, Nagler, Arnon, Raanani, Pia, Salem, Ziad
Publicado em 2013